High expression of SDF‑1 and VEGF is associated with poor prognosis in patients with synovial sarcomas
Authors:
- 2 January 2018
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 15 (3) , 2597-2603
Abstract
Stromal cell‑derived factor‑1 (SDF‑1) predicts poor clinical outcomes of certain types of cancer. Furthermore, vascular endothelial growth factor (VEGF) promotes the growth and metastasis of solid tumors. The aim of the present study was to examine the expression of SDF‑1 and VEGF in patients with synovial sarcoma and to determine their expression is correlated with unfavorable outcomes. Levels of SDF‑1 and VEGF proteins were evaluated in 54 patients with synovial sarcoma using immunohistochemical and immunofluorescence staining. Potential associations between the expression of SDF‑1 and VEGF and various clinical parameters were analyzed using Pearson's χ2 test and the Spearman‑rho test. Additionally, univariate and multivariate Cox regression analyses were used to identify potential prognostic factors, and the Kaplan‑Meier method was used to analyze the overall survival rates of patients. Low SDF‑1 and VEGF expression was detected in 20.4% (11/54) and 22.2% (12/54) of patients with synovial sarcoma; moderate expression was detected in 35.2% (19/54) and 37.0% (20/54) of patients and high expression was detected in 44.4% (24 of 54) and 40.7% (22 of 54) of patients, respectively. Levels of SDF‑1 and VEGF proteins were significantly associated with histological grade (P<0.05), metastasis (P<0.05) and American Joint Committee on Cancer staging (P<0.05). In addition, levels of SDF‑1 and VEGF expression were positively correlated with each other (P<0.001). Univariate analysis also indicated that VEGF expression was associated with shorter overall survival rates in (P<0.05), whereas multivariate analysis demonstrated that SDF‑1 expression was associated with shorter patient survival rates (P<0.05). Finally, both SDF‑1 and VEGF expression were associated with various characteristics of synovial sarcoma. Therefore, SDF‑1 expression may be a potential independent prognostic indicator in patients with synovial sarcomas.Keywords
This publication has 32 references indexed in Scilit:
- Synovial sarcoma: defining features and diagnostic evolutionAnnals of Diagnostic Pathology, 2014
- SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial–mesenchymal transition via ERK and PI3K/AKT pathwayMedical Oncology, 2014
- Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 SystemInternational Journal of Endocrinology, 2014
- Outcomes in the management of adult soft tissue sarcomasJournal of Surgical Oncology, 2014
- The Intricate Role of CXCR4 in Cancer2014
- Vascular permeability changes involved in tumor metastasisCancer Letters, 2013
- Imaging agents for the chemokine receptor 4 (CXCR4)Chemical Society Reviews, 2012
- Opportunities for improving the therapeutic ratio for patients with sarcomaThe Lancet Oncology, 2007
- Maintaining Hematopoietic Stem Cells in the Vascular NicheImmunity, 2006
- Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticityTrends in Immunology, 2004